Dr. Jacques Biton started his career with 20 years of experience in biotechnology in several pharmaceutical groups. He successfully created (2002) a pharmaceutical CRO company.
In 2007, he founded the biotechnology company Deinove, dedicated to the development of a new molecular biology platform based on the Deinocoque bacteria, and led its IPO on Alternext Euronext in 2010.
He also started up DEMETA in 2013 and was Chief Executive Officer until early 2017.
In parallel, he was instrumental in the development of several start-ups through non-operational functions
He is the author of numerous international patents covering applications in industrial biotechnology and chemistry. He holds a M.Sc. in Biochemistry and a PhD in Enzymology from UTC Compiègne.